SEC For				ОТ							~~~~	001011				
	FORM	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
Section 16. Form 4 or Form 5 obligations may continue. See					A pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											Estima
1. Name and Address of Reporting Person [*] VAN NOSTRAND ROBERT L						2. Issuer Name and Ticker or Trading Symbol <u>Intra-Cellular Therapies</u> , Inc. [ITCI]						5. Relationship of Reporting Person(s) to Issue (Check all applicable) X Director 10% Owne				
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 04/17/2023							Officer (give title Other (specify below) below)			
C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET					4. lf An	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
(Street) NEW Y	itreet) NEW YORK NY 10016				Rule	Form filed by More than One Reporting Person Rule 10b5-1(c) Transaction Indication									orting	
(City) (State) (Zip)																
1. Title of Security (Instr. 3) 2. Transa Date						ecurities Ac 2A. Deemed Execution Date, if any (Month/Day/Yea	, 3. Transaction Code (Instr.) or 4 and 5. Amount o Securities Beneficially Owned Follo		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
							Code	v	Amount	(A) or (D)	Price	Reported Transact (Instr. 3	tion(s)		(Instr. 4)	
Common Stock 04/17					7/2023	2023			10,000) A	\$13.0	5 19	,345	D		
Common Stock 04/17/					7/2023	2023			10,000) D	\$ <mark>63</mark> (2	9,345		D		
		-				curities Acq IIs, warrants						Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	se (Month/Day/Year) if any (Month/Day/Year)		Date,	4. Transaction Code (Instr 8)		Expiration Date (Month/Day/Yea			of Securiti Underlying Derivative			9. Numbe derivative Securities Beneficia Owned Following Reported Transactie (Instr. 4)	e Ownershi 5 Form: Ily Direct (D) or Indirec (I) (Instr. 4	Beneficia Ownersh t (Instr. 4)	

Date Exercisable

(3)

Expiration Date

06/24/2029

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$63.00 to \$63.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

04/17/2023

3. All shares underlying this option have vested.

\$13.05

Explanation of Responses:

Remarks:

Stock Option

(right to buy)

/s/ Lawrence J. Hineline,

04/19/2023

0

D

** Signature of Reporting Person

Amount or Number

10,000

\$0.00

of Shares

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 17, 2022.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code ۷

Μ

(A) (D)

10,000

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Attorney-in-fact Date

Title

Common

Stock